Two new hormonal agents (NHAs), abiraterone and enzalutamide, and one chemotherapeutic agent, cabazitaxel (CABA) improved overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) who progress after docetaxel. Although several analyses of patient cohorts receiving a sequence of two different new agents (NAs) after docetaxel have been published, no definite conclusions can be drawn regarding the best treatment strategy.

Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer

MAINES, Francesca;CAFFO, Orazio;TRENTIN, CHIARA;TORTORA, GIAMPAOLO;GALLIGIONI, Enzo;Bria, Emilio
2015-01-01

Abstract

Two new hormonal agents (NHAs), abiraterone and enzalutamide, and one chemotherapeutic agent, cabazitaxel (CABA) improved overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) who progress after docetaxel. Although several analyses of patient cohorts receiving a sequence of two different new agents (NAs) after docetaxel have been published, no definite conclusions can be drawn regarding the best treatment strategy.
2015
Abiraterone; Cabazitaxel; Castration-resistant; Enzalutamide; Prostate cancer; Sequence
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/953652
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 58
  • ???jsp.display-item.citation.isi??? 52
social impact